Background There are few treatment options in recurrent/metastatic (R/M) HNSCC after
progression on platinum and cetuximab, and their efficacy is disappointing. During …

6011 Background: Current treatment options for patients (pts) with recurrent/metastatic (R/M)
HNSCC who progress on platinum and cetuximab have very limited efficacy …

Burtness et al. recently published the landmark Keynote-48 study, demonstrating a survival
benefit for pembrolizumab monotherapy and pembrolizumab/chemotherapy, compared with …

6033 Background: Pembrolizumab (a humanized monoclonal antibody blocking
programmed death receptor-1 [PD-1]), and cetuximab (a chimeric monoclonal antibody …

Background: Cetuximab plus platinum and 5-fluorouracil (5-FU) is the only category 1
evidence-supported combination regimen recommended by current guidelines as first-line …

PURPOSE Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in
recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc …

Results 33 pts were enrolled March 2017-July 2019. Median age 61y (range 30-86), M: F
22: 11, ECOG (0: 1) 12: 21. Tumor sub-sites included 15 oral cavity, 13 oropharynx (11 HPV …

Summary Background Pembrolizumab (PD-1 inhibitor) and cetuximab (EGFR inhibitor) are
active as single agents and in combination with cytotoxic chemotherapy for recurrent or …

Purpose Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10
mg/kg administered once every 2 weeks, displayed durable antitumor activity in …

LBA6008 Background: Pembrolizumab (MK-3475) is a humanized monoclonal antibody that
blocks interaction of PD-1 with its ligands, PD-L1 and PD-L2, thereby promoting activity of …